Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).

George P. Kim,Eric Van Cutsem,Heinz-Josef Lenz,Udit N. Verma,Marc Saltzman,Jyotsna Fuloria,Ali Khojasteh,Martin Wiesenfeld,Frank Cihon,Andrea Wagner,Axel F Grothey

Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC).

2015

George P. Kim
Eric Van Cutsem
Heinz-Josef Lenz
Udit N. Verma
Marc Saltzman
Jyotsna Fuloria
Ali Khojasteh
Martin Wiesenfeld
Frank Cihon
Andrea Wagner
Axel F Grothey

e14649 Background: The CORRECT trial (NCT01103323) showed that REG improves overall survival (OS) vs placebo (PBO) in patients with mCRC who failed approved therapies (OS HR 0.77; 1-sided p = 0.005...

Keywords:

Colorectal cancer
Subgroup analysis
Regorafenib
Physical therapy
Pathology
Medicine
Placebo
multikinase inhibitor
overall survival
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations